Walleye Capital LLC Has $12.74 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Walleye Capital LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 30.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 560,007 shares of the company’s stock after acquiring an additional 129,411 shares during the quarter. Walleye Capital LLC owned approximately 0.88% of Viridian Therapeutics worth $12,740,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in VRDN. Quest Partners LLC raised its holdings in shares of Viridian Therapeutics by 344.0% during the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after purchasing an additional 4,692 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Viridian Therapeutics by 24.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after buying an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Viridian Therapeutics by 108.3% in the second quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after buying an additional 6,500 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Viridian Therapeutics by 14.7% in the second quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after buying an additional 1,688 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Viridian Therapeutics during the 3rd quarter valued at about $208,000.

Viridian Therapeutics Trading Down 1.5 %

Shares of VRDN opened at $21.55 on Friday. The stock’s 50-day moving average price is $22.72 and its 200 day moving average price is $17.41. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.00 and a beta of 1.10. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. As a group, research analysts predict that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Insider Activity

In related news, Director Fairmount Funds Management Llc acquired 1,600,000 shares of the company’s stock in a transaction on Friday, September 13th. The stock was purchased at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the completion of the purchase, the director now directly owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. The trade was a 86.68 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Thomas W. Beetham acquired 5,000 shares of the business’s stock in a transaction on Friday, September 27th. The shares were bought at an average cost of $23.41 per share, with a total value of $117,050.00. Following the completion of the acquisition, the chief operating officer now owns 6,000 shares of the company’s stock, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 1,626,400 shares of company stock worth $30,616,312. Corporate insiders own 0.65% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on VRDN shares. HC Wainwright boosted their target price on Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, November 14th. Royal Bank of Canada restated an “outperform” rating and issued a $44.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Oppenheimer reiterated an “outperform” rating and issued a $28.00 target price (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. BTIG Research boosted their target price on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Finally, The Goldman Sachs Group upped their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $36.33.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.